187 related articles for article (PubMed ID: 12173335)
1. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
3. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
[TBL] [Abstract][Full Text] [Related]
5. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.
Selvaggi G; Novello S; Torri V; Leonardo E; De Giuli P; Borasio P; Mossetti C; Ardissone F; Lausi P; Scagliotti GV
Ann Oncol; 2004 Jan; 15(1):28-32. PubMed ID: 14679115
[TBL] [Abstract][Full Text] [Related]
7. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
[TBL] [Abstract][Full Text] [Related]
10. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
Osarogiagbon RU; Lin CC; Smeltzer MP; Jemal A
J Thorac Oncol; 2016 Jan; 11(1):e5-16. PubMed ID: 26762752
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
[TBL] [Abstract][Full Text] [Related]
13. Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database.
Osarogiagbon RU; Yu X
J Thorac Oncol; 2012 Dec; 7(12):1798-1806. PubMed ID: 23154551
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
Qiu C; Dong W; Su B; Liu Q; Du J
J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
[TBL] [Abstract][Full Text] [Related]
15. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
Sakurai H; Asamura H; Goya T; Eguchi K; Nakanishi Y; Sawabata N; Okumura M; Miyaoka E; Fujii Y;
J Thorac Oncol; 2010 Oct; 5(10):1594-601. PubMed ID: 20736855
[TBL] [Abstract][Full Text] [Related]
16. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival.
Bréchot JM; Chevret S; Charpentier MC; Appere de Vecchi C; Capron F; Prudent J; Rochemaure J; Chastang C
Cancer; 1996 Nov; 78(10):2111-8. PubMed ID: 8918404
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
Dziadziuszko R; Merrick DT; Witta SE; Mendoza AD; Szostakiewicz B; Szymanowska A; Rzyman W; Dziadziuszko K; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Clin Oncol; 2010 May; 28(13):2174-80. PubMed ID: 20351332
[TBL] [Abstract][Full Text] [Related]
18. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
Robinson BM; Kennedy C; McLean J; McCaughan BC
J Thorac Oncol; 2011 Oct; 6(10):1691-6. PubMed ID: 21869717
[TBL] [Abstract][Full Text] [Related]
19. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
20. Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.
Toffalorio F; Radice D; Spaggiari L; Sinno V; Barberis M; Spitaleri G; Giovannini M; Delmonte A; Catania C; Noberasco C; Brambilla D; de Braud F; Veronesi G; Solli P; De Pas T
J Thorac Oncol; 2012 Jul; 7(7):1124-30. PubMed ID: 22610258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
